phorbolol myristate acetate has been researched along with Astrocytoma, Grade IV in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandrika, G; Chugh, A; Natesh, K; Ranade, D; Shastry, P | 1 |
| Cirillo, F; Colombo, D; Franchini, L; Tringali, C; Venerando, B | 1 |
2 other study(ies) available for phorbolol myristate acetate and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Fibronectins; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Naphthyridines; Neoplasm Recurrence, Local; Neural Stem Cells; Oncostatin M; Phosphatidylinositol 3-Kinases; Signal Transduction; Sirolimus; STAT3 Transcription Factor; Tetradecanoylphorbol Acetate; TOR Serine-Threonine Kinases; Vimentin | 2017 |
Glycoglycerolipid analogues inhibit PKC translocation to the plasma membrane and downstream signaling pathways in PMA-treated fibroblasts and human glioblastoma cells, U87MG.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Membrane; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fibroblasts; Glioblastoma; Glycolipids; Humans; Molecular Structure; Protein Kinase C; Signal Transduction; Stereoisomerism; Structure-Activity Relationship; Tetradecanoylphorbol Acetate | 2011 |